Home visits and flexible PrEP cut HIV incidence by 70% in rural Kenya and Uganda
Doravirine/islatravir non-inferior to Biktarvy as first-line treatment
Machine learning: shortcut or short-circuit to enhanced HIV outcomes?
Bictegravir/lenacapavir combination pill could be an option for people taking complex regimens
PrEP uptake was already low – and then came the cuts
Counting the costs of global HIV funding disruptions
Dual immune modulators delay, but don’t prevent, HIV rebound after stopping antiretrovirals
Oropharyngeal cancer is becoming more common in heterosexual men with HIV
Statin treatment reduces blood pressure in people with HIV, REPRIEVE trial shows
